All Stories

  1. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

    Article • Future Oncology, November 2015, Future Medicine

    Dr vincenza conteduca, Giovanni Lo Re

  2. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone

    Article • The Prostate, May 2015, Wiley

    Dr vincenza conteduca

  3. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

    Article • The Prostate, September 2014, Wiley

    Dr vincenza conteduca